Video Experimental Relacionado

Updated: Jan 13, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Maximización del beneficio de supervivencia con terapia de precisión basada en patrones de progresión después de

Yingnan Liu^1,2, Shuping Cheng², Taotao Dong³

¹Shandong University Cancer Center, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250117, China.

|January 7, 2026

Abstract:

This study aimed to define optimal treatment strategies for metastatic esophageal cancer with different progressive patterns after first-line immunotherapy (IO) resistance. Patients were stratified into oligoprogression and polyprogression, with further subclassifications (repeat oligoprogression [REO]/induced oligoprogression [INO]/de-novo polyprogression [DNP]/repeat polyprogression [REP]). Oligoprogression patients receiving radiotherapy (RT) had longer progression-free survival (PFS) (9.4 vs. 5.8 months, p = 0.018, q = 0.036) and overall survival (OS) (21.9 vs. 9.2 months, p = 0.012, q = 0.024), especially in the REO subgroup (PFS: 9.4 vs. 5.7 months, p = 0.0249, q = 0.0498; OS: 21.9 vs. 8.7 months, p = 0.018, q = 0.036). Polyprogression patients on IO rechallenge showed improved PFS (4.7 vs. 2.8 months, p = 0.006, q = 0.024) and OS (8.5 vs. 4.8 months, p = 0.001, q = 0.004), particularly in the REP subgroup (PFS: 5.6 vs. 2.8 months, p = 0.008, q = 0.016; OS: 5.6 vs. 2.8 months, p < 0.001, q < 0.002). Overall, RT is more important for patients with REO, while IO rechallenge could play a more dominant role for REP.

Palabras clave:

Oncología Terapéutica

Más Videos Relacionados

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Videos de Conceptos Relacionados

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.